Monica Gostissa

Monica Gostissa

Company: Egle Therapeutics

Job title: Chief Scientific Officer


Targeted Approaches to Balance Treg Function in Inflammation & Cancer 12:00 pm

Pharmacological intervention to precisely and selectively modulate regulatory T (Treg) cell function is required to restore immune system homeostasis in autoimmune disease and cancer Egle Therapeutics’ platform harnesses the selectivity of modified cytokines (muteins) combined with antibody-mediated Treg targeting Preclinical studies highlight how Egle’s multifunctional immunocytokines display novel and unanticipated mechanisms of action, resulting in…Read more

day: Day Two AM Non-Cell Based Approaches

Roundtable Discussion: Building a Strategic Roadmap to Prepare for IND & Advance to Clinical Phases 3:30 pm

Preparing for Investigational New Drug (IND) applications and transitioning to clinical phases Emphasizing the importance of strategic planning to ensure successful progression through clinical development Detailing the essential components required for a successful IND application Highlighting regulatory expectations and common pitfalls in the IND submission processRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.